186 related articles for article (PubMed ID: 33800911)
1. Dinaciclib, a Bimodal Agent Effective against Endometrial Cancer.
Howard D; James D; Murphy K; Garcia-Parra J; Pan-Castillo B; Rex S; Moul A; Jones E; Bilbao-Asensio M; Michue-Seijas S; Lutchman-Singh K; Margarit L; Francis LW; Rees P; Gonzalez D; Conlan RS
Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33800911
[TBL] [Abstract][Full Text] [Related]
2. Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer.
Howard D; James D; Garcia-Parra J; Pan-Castillo B; Worthington J; Williams N; Coombes Z; Rees SC; Lutchman-Singh K; Francis LW; Rees P; Margarit L; Conlan RS; Gonzalez D
Front Oncol; 2022; 12():1014280. PubMed ID: 36505806
[TBL] [Abstract][Full Text] [Related]
3. Pre-therapeutic efficacy of the CDK inhibitor dinaciclib in medulloblastoma cells.
Buzzetti M; Morlando S; Solomos D; Mehmood A; Cox AWI; Chiesa M; D'Alessandra Y; Garofalo M; Topham CH; Di Leva G
Sci Rep; 2021 Mar; 11(1):5374. PubMed ID: 33686114
[TBL] [Abstract][Full Text] [Related]
4. The multi-CDK inhibitor dinaciclib reverses bromo- and extra-terminal domain (BET) inhibitor resistance in acute myeloid leukemia via inhibition of Wnt/β-catenin signaling.
Marr AR; Halpin M; Corbin DL; Asemelash Y; Sher S; Gordon BK; Whipp EC; Mitchell S; Harrington BK; Orwick S; Benrashid S; Goettl VM; Yildiz V; Mitchell AD; Cahn O; Mims AS; Larkin KTM; Long M; Blachly J; Woyach JA; Lapalombella R; Grieselhuber NR
Exp Hematol Oncol; 2024 Mar; 13(1):27. PubMed ID: 38438856
[TBL] [Abstract][Full Text] [Related]
5. Dinaciclib, a cyclin-dependent kinase inhibitor, suppresses cholangiocarcinoma growth by targeting CDK2/5/9.
Saqub H; Proetsch-Gugerbauer H; Bezrookove V; Nosrati M; Vaquero EM; de Semir D; Ice RJ; McAllister S; Soroceanu L; Kashani-Sabet M; Osorio R; Dar AA
Sci Rep; 2020 Oct; 10(1):18489. PubMed ID: 33116269
[TBL] [Abstract][Full Text] [Related]
6. A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.
Lin SF; Lin JD; Hsueh C; Chou TC; Wong RJ
PLoS One; 2017; 12(2):e0172315. PubMed ID: 28207834
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial dysfunction RAD51, and Ku80 proteolysis promote apoptotic effects of Dinaciclib in Bcl-xL silenced cells.
Premkumar DR; Jane EP; Thambireddy S; Sutera PA; Cavaleri JM; Pollack IF
Mol Carcinog; 2018 Apr; 57(4):469-482. PubMed ID: 29240261
[TBL] [Abstract][Full Text] [Related]
8. Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.
Chen Y; Germano S; Clements C; Samuel J; Shelmani G; Jayne S; Dyer MJ; Macip S
Br J Haematol; 2016 Nov; 175(4):641-651. PubMed ID: 27469405
[TBL] [Abstract][Full Text] [Related]
9. Dinaciclib Induces Anaphase Catastrophe in Lung Cancer Cells via Inhibition of Cyclin-Dependent Kinases 1 and 2.
Danilov AV; Hu S; Orr B; Godek K; Mustachio LM; Sekula D; Liu X; Kawakami M; Johnson FM; Compton DA; Freemantle SJ; Dmitrovsky E
Mol Cancer Ther; 2016 Nov; 15(11):2758-2766. PubMed ID: 27550941
[TBL] [Abstract][Full Text] [Related]
10. Cyclin-dependent kinase inhibitors exert distinct effects on patient-derived 2D and 3D glioblastoma cell culture models.
Riess C; Koczan D; Schneider B; Linke C; Del Moral K; Classen CF; Maletzki C
Cell Death Discov; 2021 Mar; 7(1):54. PubMed ID: 33723248
[TBL] [Abstract][Full Text] [Related]
11. The CDK Inhibitor Dinaciclib Improves Cisplatin Response in Nonseminomatous Testicular Cancer: A Preclinical Study.
Rossini E; Tamburello M; Abate A; Zini S; Ribaudo G; Gianoncelli A; Calza S; Valcamonico F; Suardi NR; Mirabella G; Berruti A; Sigala S
Cells; 2024 Feb; 13(5):. PubMed ID: 38474332
[TBL] [Abstract][Full Text] [Related]
12. Codelivery of HIF-1α siRNA and Dinaciclib by Carboxylated Graphene Oxide-Trimethyl Chitosan-Hyaluronate Nanoparticles Significantly Suppresses Cancer Cell Progression.
Izadi S; Moslehi A; Kheiry H; Karoon Kiani F; Ahmadi A; Masjedi A; Ghani S; Rafiee B; Karpisheh V; Hajizadeh F; Atyabi F; Assali A; Mirzazadeh Tekie FS; Namdar A; Ghalamfarsa G; Sojoodi M; Jadidi-Niaragh F
Pharm Res; 2020 Sep; 37(10):196. PubMed ID: 32944844
[TBL] [Abstract][Full Text] [Related]
13. Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with
Nelson LJ; Castro KE; Xu B; Li J; Dinh NB; Thompson JM; Woytash J; Kipp KR; Razorenova OV
Cell Cycle; 2022 May; 21(10):1103-1119. PubMed ID: 35240916
[TBL] [Abstract][Full Text] [Related]
14. The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling.
Desai BM; Villanueva J; Nguyen TT; Lioni M; Xiao M; Kong J; Krepler C; Vultur A; Flaherty KT; Nathanson KL; Smalley KS; Herlyn M
PLoS One; 2013; 8(3):e59588. PubMed ID: 23527225
[TBL] [Abstract][Full Text] [Related]
15. Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro.
Cihalova D; Ceckova M; Kucera R; Klimes J; Staud F
Biochem Pharmacol; 2015 Dec; 98(3):465-72. PubMed ID: 26300056
[TBL] [Abstract][Full Text] [Related]
16. Sensitization of cervical cancer cells to radiation by the cyclin-dependent kinase inhibitor dinaciclib.
Zhang H; Chu T; Zheng J; Teng Y; Ma R; Zou L; Zhao H
Med Oncol; 2022 Dec; 40(2):68. PubMed ID: 36586018
[TBL] [Abstract][Full Text] [Related]
17. Dinaciclib synergizes with BH3 mimetics targeting BCL-2 and BCL-X
Beltrán-Visiedo M; Jiménez-Alduán N; Díez R; Cuenca M; Benedi A; Serrano-Del Valle A; Azaceta G; Palomera L; Peperzak V; Anel A; Naval J; Marzo I
Mol Oncol; 2023 Dec; 17(12):2507-2525. PubMed ID: 37704591
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of the CDK inhibitor dinaciclib in vitro and in vivo in T-cell acute lymphoblastic leukemia.
Moharram SA; Shah K; Khanum F; Marhäll A; Gazi M; Kazi JU
Cancer Lett; 2017 Oct; 405():73-78. PubMed ID: 28756008
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of cyclin dependent kinase 9 by dinaciclib suppresses cyclin B1 expression and tumor growth in triple negative breast cancer.
Rajput S; Khera N; Guo Z; Hoog J; Li S; Ma CX
Oncotarget; 2016 Aug; 7(35):56864-56875. PubMed ID: 27486754
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer.
Stephenson JJ; Nemunaitis J; Joy AA; Martin JC; Jou YM; Zhang D; Statkevich P; Yao SL; Zhu Y; Zhou H; Small K; Bannerji R; Edelman MJ
Lung Cancer; 2014 Feb; 83(2):219-23. PubMed ID: 24388167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]